These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 11269679)

  • 1. Risk factors of cyclosporine nephrotoxicity after conversion from Sandimmune to Neoral.
    Sijpkens YW; Mallat MJ; Siegert CE; Zwinderman AH; Westendorp RG; de Fijter JW; van Es LA; Paul LC
    Clin Nephrol; 2001 Feb; 55(2):149-55. PubMed ID: 11269679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
    White M; Pelletier GB; Tan A; Jesina C; Carrier M
    J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is 3-hour cyclosporine blood level superior to trough level in early post-renal transplantation period?
    Mahalati K; Lawen J; Kiberd B; Belitsky P
    J Urol; 2000 Jan; 163(1):37-41. PubMed ID: 10604309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
    Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
    Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of pre-emptive dose reduction for Sandimmune to Neoral conversion in stable renal transplant recipients.
    Hricik DE; Dixit A; Knauss TC; Donley V; Bartucci MR; Schulak JA
    Clin Transplant; 1998 Dec; 12(6):575-8. PubMed ID: 9850454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
    Carstens J
    Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year.
    Neumayer HH; Budde K; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J; Luft FC
    Clin Nephrol; 1996 May; 45(5):326-31. PubMed ID: 8738665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.
    van Mourik ID; Thomson M; Kelly DA
    Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
    Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
    Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in a single center.
    Tinawi M; Miller L; Bastani B
    Clin Transplant; 1997 Feb; 11(1):1-8. PubMed ID: 9067686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Conversion from +Sandimmune to Neoral in kidney transplant recipients treated with cyclosporine and ketoconazole].
    Videla C; Vega J; Borja H; Gatica A; Clavero R; Aldunate T
    Rev Med Chil; 1997 Apr; 125(4):438-45. PubMed ID: 9460285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
    Cantarovich M; Besner JG; Barkun JS; Elstein E; Loertscher R
    Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine nephrotoxicity: associated allograft dysfunction at low trough concentration.
    Jankauskiene A; Druskis V; Laurinavicius A
    Clin Nephrol; 2001 Dec; 56(6):S27-9. PubMed ID: 11770808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral.
    Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R
    Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine dose reduction in stable renal transplant patients with high C2 level: simplified method of single C2 measurement and individualization of C0 target.
    Higgins RM; Kanji H; Hernon M; Harrison P; Lam FT; Kashi SH
    Transpl Int; 2005 Jul; 18(7):806-10. PubMed ID: 15948859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
    Akhlaghi F; Gonzalez L; Trull AK
    J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function.
    Qazi YA; Forrest A; Tornatore K; Venuto RC
    Clin Transplant; 2006; 20(3):313-7. PubMed ID: 16824147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppression in live-related donor renal transplantation.
    Iman A; Rao M; Juneja R; Jacob CK
    Natl Med J India; 2001; 14(2):75-80. PubMed ID: 11396322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent predictors of renal dysfunction after heart transplantation in patients with normal pretransplant renal function.
    Garrido IP; Crespo-Leiro MG; Paniagua MJ; Muñiz J; Vázquez-Rey E; Pérez-Fernández R; García-Lara J; Cuenca-Castillo JJ; Castro-Beiras A
    J Heart Lung Transplant; 2005 Sep; 24(9):1226-30. PubMed ID: 16143237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.